Yasha Modi, MD - Putting Evidence Into Practice: Case-Based Strategies for Long-Acting Anti-VEGF Agents in nAMD

Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.

Please visit answersincme.com/SAM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the importance of molecular testing in the treatment of advanced squamous NSCLC with immunotherapy. Upon completion of this activity, participants should be better able to: Assess the role of molecular testing in guiding first-line treatment selection for patients with advanced squamous non–small-cell lung cancer (NSCLC); Review the practical implications of the clinical evidence evaluating preferred combination immunotherapy regimens for the initial management of advanced squamous NSCLC; and Outline clinical, evidence-based strategies to optimize the provision of long-term care for patients with advanced squamous NSCLC receiving combination immunotherapy regimens.

Please visit answersincme.com/CED860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neovascular age-related macular degeneration (nAMD) discusses practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy. Upon completion of this activity, participants should be better able to: Select the optimal long-acting anti–vascular endothelial growth factor (VEGF) therapy for individual patients with neovascular age-related macular degeneration (nAMD); Integrate practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy in patients with nAMD; and Outline patient-centered strategies to facilitate adherence to anti-VEGF therapy.

Please visit answersincme.com/860/97851223-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the growing importance of immunotherapy in the management of limited-stage small-cell lung cancer (LS-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Identify clinical factors that drive treatment decision-making for patients with SCLC.

Please visit answersincme.com/860/96036801-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss the latest in diagnosis and optimized management of Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Describe strategies to assess suspected nontuberculous mycobacterial (NTM) lung disease; Review guideline-recommended treatment plans for Mycobacterium avium complex (MAC) lung disease; Explain the clinical significance of the latest evidence for emerging first-line therapies for MAC lung disease, in the context of current standard of care; and Outline best practices to enhance outcomes for patients with MAC lung disease, including those receiving approved or emerging first-line therapies.

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.

Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence.

Please visit answersincme.com/MPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myelodysplastic syndromes discusses strategies for the management of FLT3-mutated acute myeloid leukemia. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML); Recognize the clinical significance of the evidence for approved FLT3 inhibitors in the first-line treatment of newly diagnosed, FLT3-mutated AML; Formulate strategies to maximize the impact of FLT3 inhibitors in the management of patients with newly-diagnosed, FLT3-mutated AML.

Please visit answersincme.com/VYT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses the management of vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Identify VMS as a consequence of menopause; Evaluate the efficacy and safety of new and emerging neurokinin (NK)-targeted therapies for VMS; Implement shared decision-making for optimal VMS treatment outcomes

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.